Can metformin cause epistaxis (nosebleeds)?

Metformin Does Not Cause Epistaxis

Metformin is not associated with epistaxis (nosebleeds) and is not listed as a known cause of bleeding complications. This is clearly established in both the FDA drug labeling and clinical practice guidelines for epistaxis management.

Evidence from Drug Labeling

The FDA-approved metformin prescribing information 1 comprehensively lists side effects and does not include epistaxis or any bleeding disorders. The documented adverse effects are:

• Common side effects: Diarrhea, nausea, upset stomach (occur in most patients initially)
• Serious but rare: Lactic acidosis (the primary safety concern)
• Other effects: Metallic taste (~3% of patients), vitamin B12 deficiency with long-term use, hypoglycemia (only when combined with other glucose-lowering agents)

Notably absent from this extensive safety profile is any mention of bleeding, epistaxis, or coagulation abnormalities.

Evidence from Epistaxis Guidelines

The 2020 American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guideline on Epistaxis 2, 3 provides a comprehensive list of medications that increase nosebleed risk:

• Anticoagulants (warfarin, direct oral anticoagulants)
• Antiplatelet medications (aspirin, clopidogrel)
• Intranasal corticosteroids (relative risk 2.74 for epistaxis)
• Other intranasal medications and drugs of abuse

Metformin is conspicuously absent from this list despite the guideline's thorough review of medication-related epistaxis risk factors.

Clinical Context

The guideline emphasizes that when evaluating epistaxis patients, clinicians should specifically inquire about:

• Anticoagulant and antiplatelet medication use
• Recent dosage changes in these medications
• INR levels for warfarin users
• Intranasal medication use

The systematic omission of metformin from these recommendations, combined with its absence from the FDA labeling, provides strong negative evidence.

Addressing the Single Case Report

One isolated case report 4 from 2011 described a "bleeding episode" after metformin dose escalation. However:

• This represents the lowest level of evidence (single case report)
• No mechanism of action is established
• It contradicts both FDA labeling and clinical guidelines
• The temporal association may be coincidental
• The specific type of bleeding is not clearly defined as epistaxis

In clinical practice, when a patient on metformin presents with epistaxis, look for the actual culprits:

• Anticoagulants (warfarin has 2-4x higher epistaxis rates than DOACs 5)
• Antiplatelet agents
• Intranasal corticosteroids
• Hypertension (though causality is debated)
• Underlying bleeding disorders
• Local nasal factors (trauma, dryness, foreign bodies)

Metformin should not be discontinued or suspected as the cause of nosebleeds.